New Test Com.pl.i.t.DX Liquid Breast for Targeted Therapies

logo
login
Login
Services
Services
About master page
About
News
News
Contact
Contact
EN

Com.pl.i.t DX Liquid Breast


The assay Com.pl.i.t DX Liquid Breast has been designed for postmenopausal women with recurrent or metastatic ER+/HER2- breast cancer and is a strong indicator on whether the patient should undergo specific targeted treatments.

ORDER NOW

The assay Com.pl.i.t DX Liquid Breast has been designed for postmenopausal women with recurrent or metastatic ER+/HER2- breast cancer and is a strong indicator on whether the patient should undergo specific targeted treatments.

 

The Com.pl.i.t DX Liquid Breast Test is suitable for:

  • Patients with non-operable tumors and patients with limited or inadequate tissue biopsy material.
  • Patients with multiple metastases.
  • Patients under treatment or after completion of treatment. In this case it gives insight in the eventual arise of new targetable mutations or resistance mutations to the treatment used.

 

The Com.pl.i.t DX Liquid Breast Test:

 

  • Determines the molecular profile of the tumor such as gene mutations and Copy Number Variations for inoperable tumors.
  • Designates the on-label drug that targets the mutated gene(s) or the pathway that the gene(s) are involved.
  • Identifies the mutations associated with resistance to targeted treatment.
  • Recommends off-label therapies and/or indicates therapies that are currently in clinical trials.

 

In more detail, the test is highly recommended for targeted treatment decisions for:

  • Postmenopausal women with advanced or metastatic ER+/HER2- breast cancer after relapse on prior therapy, in order to decide on treatment with Elacestrant, based on ESR1 gene mutations.
  • Postmenopausal women with advanced or metastatic ER+/HER2- breast cancer after relapse on prior therapy, in order to decide on treatment with Alpelisib, based on PIK3CA gene mutations.

Postmenopausal women with advanced or metastatic breast cancer after relapse on prior therapy, in order to decide on off-label or clinical trial treatments.

 

Table of Genes

 

 

BIOMARKERS ASSOCIATED WITH FDA APPROVED THERAPIES

 

Change cookies consent Revoke cookies consent